Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 12% revenue increase, improved gross margins, and a shift from net loss to net income, indicating strong financial performance. Despite regulatory approval risks, the company's financial health and operational efficiency are promising. The absence of negative insights from the Q&A further supports a positive sentiment. Given the company's growth and improved cash flow, a positive stock price movement between 2% to 8% is likely over the next two weeks.
Key Financial Performance
Revenue $18.2 million, a 12% increase year-over-year, driven by strong sales of core dermatology products.
Gross Margin 72%, up from 68% year-over-year, attributed to improved operational efficiencies and cost management.
Net Income $2.5 million, compared to a net loss of $1.8 million in the prior year, due to increased revenue and better expense control.
Operating Expenses $10.3 million, a 5% increase year-over-year, primarily due to higher R&D investments.
Cash Flow from Operations $3.8 million, a significant improvement from $0.5 million in the prior year, reflecting better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: Management highlighted the risk of not receiving regulatory approvals, which could adversely impact future performance and operational results.
Forward-Looking Statements: Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially, posing challenges to the company's strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alloush COO
Benesch CFO
Brandon Folkes
CFO Corporate
Claude Maraoui
Co LLC
Conference Instructions
Corporate Claude
Corporate Ramsey
Counsel Secretary
Cox Lake
Director Benesch
Division Brandon
Division Mayank
Division PM
Division Scott
EDT afternoon
Folkes HC
General Counsel
HC Wainwright
Instructions Participants
Jaclyn statement
Journey Medical
LLC Research
Maraoui Founder
Nelson Cox
PM EDT
Ramsey Alloush
Research Division
Scott Henry
Secretary Nelson
Wainwright Co
day Senior
DERM Transcript
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call highlights a 12% revenue increase, improved gross margins, and a shift from net loss to net income, indicating strong financial performance. Despite regulatory approval risks, the company's financial health and operational efficiency are promising. The absence of negative insights from the Q&A further supports a positive sentiment. Given the company's growth and improved cash flow, a positive stock price movement between 2% to 8% is likely over the next two weeks.
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call reveals strong financial performance with a 10% revenue increase and improved margins. Emrosi's launch is successful, and management anticipates significant growth. Despite increased SG&A expenses, financial health is robust, with a positive cash position and working capital. The Q&A section confirms management's optimistic outlook for Emrosi's growth and improved gross margins. Overall, the positive financial metrics, optimistic guidance, and market expansion plans suggest a positive stock price movement over the next two weeks.
Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call reveals strong revenue growth driven by EMROSI, improved EBITDA, and positive cash flow. The Q&A section highlights successful prescriber expansion and revenue per script improvements, although there are concerns about gross-to-net revenue guidance and prescriber retention data. Despite these uncertainties, the overall sentiment is positive due to the strong financial metrics, optimistic guidance, and strategic focus on expanding EMROSI's market presence.
Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reflects mixed sentiments. While there is optimism around EMROSI's launch and market access, concerns exist regarding generic competition affecting revenue, increased SG&A expenses, and net losses. The Q&A section highlighted management's reluctance to provide detailed guidance, which could unsettle investors. However, improved gross margins and strong initial revenue from EMROSI provide some optimism. The overall sentiment is neutral, with potential for both positive and negative outcomes depending on EMROSI's future performance.
DERM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
